An update from Oxford after a quarter that saw a global vaccine for the world and record stats from our innovation cluster.
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
Fake drugs, vaccines a thing of the past with PrOXisense breakthrough technology
Counterfeit medicine, which can prove both costly and deadly, target of new collaboration with Oxford University.
Oxford University Innovation Q3 2020 Update
Your quarterly review of activity from Oxford University Innovation.
Oxford Brain Diagnostics awarded FDA Breakthrough Device Designation for technology to predict Alzheimer’s Disease
The breakthrough diagnostics platform will offer clinicians a new path to evaluating the potential advancement of Alzheimer's Disease.
SpyBiotech and SII dose first subjects in trial of COVID-19 vaccine
Oxford spinout Spybiotech partners Serum Institute of India on new potential vaccine for COVID-19.
Careers advice app is first Singapore-based startup from Oxford University Innovation incubator
Careershe aims to provide smartphone-based career advice to Chinese students
OUI Q2 2020 Update
OUI's momentum continues to build even under lockdown in a COVID-defying quarter.
Oxford scientists form spinout to launch rapid Covid-19 virus test
New Oxford spinout Oxsed will lead commercialisation of rapid, cost-effective COVID-19 test.
Oxford Vacmedix announces collaboration to develop vaccine and diagnostic tests for Covid-19
Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19
OUI Q1 2020 Update
Welcome to the Oxford University Innovation Q1 2020 update. OUI is now a month into its status as a virtual company with the entire office working from home, but we remain very much open for business. Below you’ll find all the usual updates from OUI and news from our spinouts, as well as an update on how Oxford is responding to the ongoing crisis.